Fulcrum Therapeutics (FULC) Aperçu de l'action
Fulcrum Therapeutics, Inc. est une société biopharmaceutique en phase clinique qui développe des petites molécules pour améliorer la vie des patients souffrant de maladies génétiquement définies dans des domaines où les besoins médicaux non satisfaits sont importants aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
FULC Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fulcrum Therapeutics, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$6.59 |
| Plus haut sur 52 semaines | US$15.74 |
| Plus bas sur 52 semaines | US$5.88 |
| Bêta | 3.01 |
| Variation sur 1 mois | -12.48% |
| Variation sur 3 mois | -40.09% |
| Variation sur 1 an | 7.68% |
| Variation sur 3 ans | 121.14% |
| Variation sur 5 ans | -26.78% |
| Évolution depuis l'introduction en bourse | -51.19% |
Nouvelles et mises à jour récentes
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. By way of example, Fulcrum...
Fetal Hemoglobin Induction Will Reshape Sickle Cell Care And Broaden Long Term Hematology Potential
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on small molecule treatments for genetically defined diseases, with an emphasis on sickle cell disease and hematologic conditions. What are the underlying business or industry changes driving this perspective?Recent updates
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. By way of example, Fulcrum...Fetal Hemoglobin Induction Will Reshape Sickle Cell Care And Broaden Long Term Hematology Potential
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on small molecule treatments for genetically defined diseases, with an emphasis on sickle cell disease and hematologic conditions. What are the underlying business or industry changes driving this perspective?
Oral Fetal Hemoglobin Induction Will Reshape Severe Sickle Cell Treatment Over The Long Term
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on developing oral fetal hemoglobin inducers for sickle cell disease and other hemoglobinopathies. What are the underlying business or industry changes driving this perspective?Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion
Summary Fulcrum Therapeutics pivots to pociredir for severe sickle cell disease after discontinuing losmapimod. Pociredir’s Phase 1 PIONEER data shows 7/12 patients hitting the ≥20% HbF threshold, but mean HbF just misses the mark. FULC’s valuation is tied almost entirely to pociredir, with a risk-adjusted NPV of $136 million and $352.3 million in cash. I maintain a cautious 'Hold' rating; upside is limited by actual TAM and risk profile despite potential for accelerated approval. Read the full article on Seeking AlphaWe're Not Very Worried About Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Fulcrum Therapeutics...Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 1.7x Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) is a stock...There's Reason For Concern Over Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Massive 34% Price Jump
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders have had their patience rewarded with a 34% share price jump in...We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders that were waiting for something to happen have been dealt a...Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly
Summary Fulcrum Therapeutics, Inc.'s stock plummeted over 60% after its lead candidate, losmapimod, failed to meet primary and secondary endpoints in a Phase 3 study for FSHD. Despite prior optimism and significant investments from Sanofi and positive analyst ratings, the REACH trial's results were disappointing, leading to the suspension of the losmapimod program. Fulcrum's management, facing leadership changes and a challenging market, will now focus on its other clinical-stage candidate, pociredir, for sickle cell disease. With a market cap of $550m and nearly $300m in cash, the future value of Fulcrum's pipeline remains uncertain amidst intense competition. Read the full article on Seeking AlphaWill Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Fulcrum...Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
The latest analyst coverage could presage a bad day for Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ), with the analysts...We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts
Today is shaping up negative for Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders, with the analysts delivering...Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M
Fulcrum Therapeutics press release (NASDAQ:FULC): Q2 GAAP EPS of -$0.83 misses by $0.17. Revenue of $1.9M (-56.6% Y/Y) misses by $1.06M. As of June 30, 2022, cash, cash equivalents, and marketable securities were $169.0M, as compared to $218.2M as of December 31, 2021. Based on current operating plans, including successful implementation of the operational realignment, Fulcrum expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into mid-2024.Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave
Fulcrum Therapeutics (NASDAQ:FULC) on Monday said its chief medical officer Christopher Morabito will be leaving the company effective July 13. FULC said its R&D president Judith Dunn will be the interim chief medical officer while the company searches for a new executive. FULC said Dunn had assumed direct oversight of all clinical activities and related functions. Prior to joining Fulcrum (FULC), Dunn had held multiple leadership positions including leading global clinical development for Roche (OTCQX:RHHBY) (OTCQX:RHHBF). FULC stock earlier closed -4.1% at $5.69.Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder
Fulcrum Therapeutics (NASDAQ:FULC) said the first patient was dosed in a phase 3 trial of losmapimod to treat Facioscapulohumeral Muscular Dystrophy (FSHD). FSHD is a rare progressive disorder characterized by muscle weakness and wasting and initially affects the face, shoulder blades and upper arms. The study, dubbed REACH, will enroll ~230 adults at over 30 sites in North America and Europe and evaluate losmapimod, given orally as a 15-mg tablet twice a day, against placebo. The company said that a phase 2 trial, called ReDUX4, showed that losmapimod was superior to placebo and slowed disease progression and helped maintain function in adults with FSHD.Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling
Fulcrum lost hugely this month after announcing data from an early Sickle Cell Disease trial. The other program is also beset with issues. This does not look attractive to us right now.These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat
Market forces rained on the parade of Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders today, when the analysts...Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Rendement pour les actionnaires
| FULC | US Pharmaceuticals | US Marché | |
|---|---|---|---|
| 7D | -7.3% | 1.9% | -0.8% |
| 1Y | 7.7% | 41.8% | 27.1% |
Rendement vs Industrie: FULC a sous-performé le secteur US Pharmaceuticals qui a rapporté 41.8 % au cours de l'année écoulée.
Rendement vs marché: FULC a sous-performé le marché US qui a rapporté 27.1 % au cours de l'année écoulée.
Volatilité des prix
| FULC volatility | |
|---|---|
| FULC Average Weekly Movement | 10.9% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: FULC n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de FULC ( 11% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2015 | 55 | Alex Sapir | www.fulcrumtx.com |
Fulcrum Therapeutics, Inc. est une société biopharmaceutique en phase clinique qui développe des petites molécules pour améliorer la vie des patients atteints de maladies génétiquement définies dans des domaines où les besoins médicaux sont importants et non satisfaits aux États-Unis. Son produit candidat en phase clinique est le pociredir, un inducteur d'hémoglobine fœtale, qui est en phase 1b d'essai clinique pour le traitement de la drépanocytose et de la bêta-thalassémie. La société découvre également des programmes pour le traitement de l'anémie noire diamantine, des syndromes d'insuffisance médullaire, de nouveaux inducteurs de l'hémoglobine fœtale et des troubles fibrotiques.
Fulcrum Therapeutics, Inc. Résumé des fondamentaux
| FULC statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$423.12m |
| Bénéfices(TTM) | -US$76.12m |
| Recettes(TTM) | n/a |
Le site FULC est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| FULC compte de résultat (TTM) | |
|---|---|
| Recettes | US$0 |
| Coût des recettes | US$56.78m |
| Marge brute | -US$56.78m |
| Autres dépenses | US$19.33m |
| Les revenus | -US$76.12m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -1.14 |
| Marge brute | 0.00% |
| Marge bénéficiaire nette | 0.00% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de FULC?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 22:19 |
| Cours de l'action en fin de journée | 2026/05/21 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Fulcrum Therapeutics, Inc. est couverte par 17 analystes. 11 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |